Founded in 2020 and based in Cambridge, Massachusetts, Tiba Biotech is a private, preclinical biotech emerging from a 5-year sponsored research program at M.I.T. and the Whitehead Institute. The company is developing a proprietary RNA platform that integrates a novel, biodegradable delivery nanoparticle with advanced computational RNA design, aiming to create safer and more potent vaccines and therapeutics. With a seasoned leadership team and backing from global foundations and government partners like NIH, BARDA, and CEPI, Tiba is initially targeting influenza vaccines while building a pipeline in oncology and genetic medicines.
Integrated platform combining a fully biodegradable nanoparticle delivery system with computational RNA design for optimized potency, safety, and stability of mRNA vaccines and therapeutics.
Funding History
2
Total raised:$3.1M
Grant$650KNational Institutes of Health
Seed$2.5MUndisclosed
Opportunities
The validated success of mRNA vaccines opens a massive market for next-generation improvements in safety and efficacy, particularly in seasonal vaccines like influenza.
The platform's potential application in therapeutic areas such as oncology and gene therapy represents an even larger long-term market opportunity if the technology proves effective for repeat dosing and targeted delivery.
Risk Factors
The company is at a high-risk, preclinical stage where its novel delivery and RNA design technology must still prove itself in animal models and, crucially, in human trials.
It faces intense competition from large, established mRNA companies and well-funded startups all pursuing next-generation delivery solutions.
Competitive Landscape
Tiba operates in the highly competitive field of RNA therapeutics, competing directly with giants like Moderna and BioNTech/Pfizer, as well as numerous biotechs focused on novel lipid nanoparticles (LNPs) and other delivery modalities (e.g., Arcturus, CureVac, Translate Bio (acquired), and many stealth startups). Differentiation hinges on demonstrating superior safety/efficacy of its biodegradable platform.
